Criteria to qualify for this study: Drug used in study:
  • Received 1 to 3 prior therapies for Multiple Myeloma with documented PD on last regimen; achieved a response to at least 1 prior therapy.

MM 99

A study of Ixazomib + Daratumumab (IDd) in relapse and/or refractory Multiple myeloma (RRMM)

Criteria to qualify for this study: Drug used in study:
  • High risk MGUS must have < 10% plasma cells and < 3.0 g/dL M-spike; Low risk smoldering multiple myeloma must only present with 1 of the following criterion, Monoclonal Protein < = 3 g/dL or FCL ratio < 0.125 or <8.

MM 106

A Phase II Study of the CD38 Antibody Daratumumab in patients with High-risk MGUS and Low-Risk Smoldering Multiple Myeloma

Criteria to qualify for this study: Drug used in study:
  • Relapsed CAR-T

MM 88 Poseida PBMCS – 101 – 001

Open-Label, Multi-Center, Single Ascending Dose Study to Assess the Safety of P-BMCA-101 in Subjects with Relapsed and/or Refractory Multiple Myeloma.

Criteria to qualify for this study: Drug used in study:
  • Post Auto

MM 82

Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma.

Criteria to qualify for this study: Drug used in study:
  • R/R, AML/MM/DLBCL

HEMREF 51 Medimmune

A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of MEDI7247 in Patients with Selected Relapsed/Refractory Hematological Malignancy "ECOG 0-1, Liver Function Tests: AST and ALT ? 3 × ULN; ? 5 × the ULN for either value if due to leukemia or lymphoma involvement, and serum TBL ? 1.5 × ULN, unless consistent with Gilbert’s syndrome (ratio between total and direct bilirubin > 5), for which TBL ? 2.5 × ULN is allowed. AML - Hydroxyurea, if clinically indicated, is permitted but must be stopped 24 hours prior to the first scheduled dose of MEDI7247 MM-May have received approved agents or radiation within 14 days OR immunotherapy within 28 days of the first scheduled dose of MEDI7247"

Criteria to qualify for this study: Drug used in study:
  • Relapsed / Refractory
  • 2 part, multicenter, open label, phase 1a/1b study of TTI-622 in patients with advanced relapsed or refractory lymphoma and multiple myeloma

HR 56 TTI-622-01

A Phase 1a/1b dose escalation and expansion trial of TTI-622 in patients with Advanced Relapsed or Refractory Lymphoma or Myeloma.

Criteria to qualify for this study: Drug used in study:
  • Relapsed or refractory
  • Serum M protein must be at least 1.0 g/dL
  • Urine M proteint must be at least 200 mg/24hr
  • Patients requiring anticoagulation with warfarin are excluded
  • ANC must be at least 1000
  • PLT must be at least 75
  • HGB must be at least 8

MM 51 SCRI PCYC-1119-CA

A Multicenter Phase 1/2b Study of the Bruton's Tyrosine Kinase Inhibitor, Ibruitnib (PCI-32765), in Combination with Carfilzomib (Kyprolis) in Subjects with Relapsed or Relapsed and Refractory Multiple Myeloma